STAT+: Experts scrutinize Huidagene’s disclosures after patient death

Merck and Moderna reported that their personalized mRNA cancer vaccine succeeded in a randomized late-stage trial for the first time, a milestone for the approach that scientists have long hoped would become a major oncology breakthrough. The excerpt gives no further trial data.

The same newsletter headlines a STAT+ exclusive about experts scrutinizing Huidagene's disclosures after a patient death, though the excerpt does not include the details of that story.